Form 4: Incyte Corp Executive Christiana Stamoulis Acquires 25,516 Stock Options
SEC Form 4 Filing
Incyte Corp's EVP & Chief Financial Officer, Christiana Stamoulis, has been granted 25,516 employee stock options.
Summary
- Christiana Stamoulis, EVP & Chief Financial Officer of Incyte Corp, has acquired 25,516 employee stock options.
- The options have an exercise price of $71.93 per share.
- The options become exercisable in 37 installments starting January 17, 2025.
- The first 25% of the options will vest on July 15, 2025, with the remaining options vesting monthly over the following three years.
- The options expire on January 16, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns executive interests with company performance. There are no negative implications.
Positives
- The grant of stock options to a key executive aligns their interests with the company's long-term performance.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
The vesting schedule of the options suggests a long-term incentive for the executive to contribute to the company's success.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology and pharmaceutical industry, aligning executive interests with shareholder value.
Comparison to Industry Standards
- Stock option grants are a standard practice for executive compensation in the pharmaceutical industry.
- The vesting schedule of 3 years with a cliff vest of 25% is a common structure for these types of grants.
- Companies like Regeneron, Gilead, and Vertex also use stock options as part of their executive compensation packages.
Stakeholder Impact
- The stock option grant aligns the executive's interests with those of shareholders, potentially leading to increased shareholder value.
Key Dates
| Date | Description |
|---|---|
| 01/17/2025 | Date of the stock option grant and the start of the vesting period. |
| 07/15/2025 | Date when the first 25% of the options vest. |
| 01/16/2035 | Expiration date of the stock options. |
| 01/22/2025 | Date the form was signed. |
Keywords
stock options, executive compensation, insider trading, Incyte Corp, vesting, equity, Christiana Stamoulis
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.